Archive: News
-
Experts Anticipate a Growing Menu of Frontline Options in Liver Cancer
Panelists review data for lenvatinib (Lenvima), and novel drugs under investigation in the second line for HCC, such as cabozantinib (Cabometyx/Cometriq) and pembrolizumab (Keytruda).
Category: News
-
Not All Pancreatic Cancers are the Same: Some Have Treatable Mutations
There are subgroups of patients with pancreatic cancer whose tumors are particularly susceptible to certain therapies.
Category: News
-
Marshall Makes the Case for Molecular Sorting in Gastrointestinal Disease
Oncologists have been slow to introduce targeted and immune therapies into the treatment of gastrointestinal cancers, but that is changing, and poor patient survival statistics call for a continuation of this trend.
Category: News
-
Aligning Effective Treatments and Communication to Optimize Care of Patients With Metastatic Colorectal Cancer
Learn how John L. Marshall, MD, and Bobbie Khan, MS, RN, OCN, involve patients with metastatic colorectal cancer in their own care in order to provide optimal treatment.
Category: News
-
Advancing Care Across the Spectrum of Pancreatic Cancer
How are recent advances in treatment of pancreatic cancer affecting patient outcomes?
Category: News
-
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating Pancreatic Cancer patients with certain genetic mutations.
Category: News
-
How Microsatellite Instability Works in Colorectal Cancer
Understanding one’s biomarkers, such as microsatellite stable (MSS) or instable (MSI) status in tumors, is key in understanding how a patient with colorectal cancer may be treated.
Category: News
-
Helping Caregivers: Advice, Support and More
At the GI Cancer Patient Summit, a panel of caregivers drew upon personal experience to offer advice and discuss what more can be done for individuals in this role of the cancer journey.
Category: News
-
Marshall Details Treatment Options for Patients With GI Cancers in 2 Case Studies
John Marshall, MD, recently shared the treatment considerations and decisions he makes when treating patients with gastrointestinal (GI) cancers
Category: News
-
Immunotherapy Hype and Oncologists’ Fear of Failure Drive ‘Hail Mary’ Treatments
John Marshall speaks with Leonard Saltz and Tanios Bekaii-Saab about the destructive trend of trying experimental drugs before having the data, and the new ‘right to try’ law.
Category: News